Diabetes, Obesity & Metabolism最新文献

{"title":"The Interconnected Immune Landscape: Islet Autoantibody Prevalence in Children Belonging to General and At-Risk Populations.","authors":"Mariangela Martino, Rosanna Squintani, Valentina Pampanini, Maria Elisa Amodeo, Paolo Ciampalini, Annalisa Deodati, Novella Rapini, Francesca Silvestri, Chiara Maria Trovato, Francesca Ferretti, Antonella Diamanti, Giorgia Bracaglia, Stefano Ceccarelli, Ottavia Porzio, Stefano Cianfarani, Riccardo Schiaffini","doi":"10.1111/dom.71136","DOIUrl":"10.1111/dom.71136","url":null,"abstract":"","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":"10840-10845"},"PeriodicalIF":6.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148534633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metformin Alleviates High Glucose-Induced Pyroptosis and Inflammatory Responses in HK-2 Cells via SIRT1-Associated Regulation of the TXNIP/NLRP3 Pathway.","authors":"Shuyu Shi, Bing Wang, Yang Zhou, Qi Li, Yusheng Hou, Xinyi Zhang, Qiuyue Wang","doi":"10.1111/dom.71248","DOIUrl":"10.1111/dom.71248","url":null,"abstract":"<p><strong>Background: </strong>Diabetic kidney disease (DKD) is a major cause of renal failure and end-stage renal disease. Pyroptosis, a Gasdermin-dependent inflammatory form of programmed cell death, has been implicated in DKD progression. Metformin has shown renoprotective effects in DKD; however, the underlying mechanisms remain unclear.</p><p><strong>Objective: </strong>To investigate whether metformin attenuates high glucose-induced pyroptosis and inflammatory responses in HK-2 cells through SIRT1-mediated regulation of the TXNIP/NLRP3 pathway.</p><p><strong>Methods: </strong>Bioinformatics analyses were performed to identify DKD-related pyroptosis-associated genes and enriched pathways. Serum TXNIP and IL-1β levels were measured in patients with type 2 diabetes mellitus stratified by urinary albumin-to-creatinine ratio (UACR). HK-2 cells were exposed to high glucose (30 mM) to establish an in vitro injury model. Oxidative stress, pyroptosis-related signalling and inflammatory cytokines were evaluated using molecular and immunological assays. SIRT1 modulation and TXNIP silencing were used to investigate pathway regulation. Chromatin immunoprecipitation assays were performed to assess SIRT1 occupancy and histone acetylation status within the TXNIP promoter region.</p><p><strong>Results: </strong>Pyroptosis-related genes were mainly enriched in inflammatory and NLRP3 inflammasome-associated pathways. Serum TXNIP and IL-1β levels were elevated in DKD patients and positively correlated with UACR. In HK-2 cells, high glucose reduced SIRT1 expression and activated the TXNIP/NLRP3 inflammasome pathway, accompanied by increased GSDMD cleavage and inflammatory cytokine expression. Metformin partially reversed these changes. Altered SIRT1 activity was also associated with changes in H3K56 acetylation enrichment within the TXNIP promoter region.</p><p><strong>Conclusion: </strong>Metformin may alleviate high glucose-induced pyroptosis and inflammatory responses in HK-2 cells, potentially through modulation of SIRT1-associated TXNIP/NLRP3 signalling and TXNIP-related chromatin acetylation status.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":"10343-10369"},"PeriodicalIF":6.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148786242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transitioning From Sensor-Augmented Insulin Pumps to Hybrid Closed-Loop Systems and the Risk of Progression of Diabetic Retinopathy in Type 1 Diabetes.","authors":"Maria S Varughese, Ananth U Nayak, Louise Payne, Lakshminarayanan Varadhan","doi":"10.1111/dom.71290","DOIUrl":"10.1111/dom.71290","url":null,"abstract":"","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":"10907-10910"},"PeriodicalIF":6.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148838480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dysglycaemia and Autonomic Dysfunction: The Diabetes Prevention Program Outcomes Study.","authors":"Justin B Echouffo-Tcheugui, Xun Liu, Elsayed Z Soliman, Xavier Pi-Sunyer, Sherita H Golden, Sam Dagogo-Jack, Neil H White, Matthew Budoff, Uzoma Ibebuogu, Christine Darwin, William C Knowler, Marinella Temprosa","doi":"10.1111/dom.71111","DOIUrl":"10.1111/dom.71111","url":null,"abstract":"<p><strong>Aim: </strong>Limited data on the link between various measures of glycemia and metabolism and autonomic dysfunction exist. We assessed the association of fasting plasma glucose [FPG], glycated haemoglobin [HbA_1C], fasting insulin, and HOMA-IR and cardiac autonomic function measures separately for men and women in the Diabetes Prevention Program Outcomes Study (DPPOS).</p><p><strong>Methods: </strong>We included DPPOS participants with ECG-based heart rate variability (HRV) measured at the 10-year examination. Resting heart rate (HR), standard deviation of all normal-to-normal intervals (SDNN), and root mean square of successive differences between normal-to-normal intervals (rMSSD) were measured. Multivariable linear regression models assessed the cross-sectional associations of FPG, HbA_1C, and fasting insulin and HOMA-IR with cardiac autonomic function measures.</p><p><strong>Results: </strong>Among 2266 participants (mean age 65 years, 68.2% women, 53.4% White, 43.7% with prediabetes and 56.3% with diabetes at the time of evaluation), HbA_1C, FPG, fasting insulin and HOMA IR were positively associated with high resting HR in men and women. HbA_1C and FPG were inversely associated with rMSSD (β [95% CI] per SD: -0.08 [-0.14, -0.03] and -0.08 [-0.13, -0.03]) and SDNN (-0.08 [-0.12, -0.03] and -0.07 [-0.11, -0.02]) among women, but not in men. Fasting insulin was inversely associated with rMSSD in the men (-0.09 [-0.18, 0.00]). HOMA-IR was inversely associated with rMSSD in men (-0.11 [-0.20, -0.02] and women -0.07 [-0.12, -0.02]). HOMA-IR was associated with SDNN only in women (-0.05 [-0.10, 0.00]).</p><p><strong>Conclusions: </strong>Markers of dysglycaemia are associated with worse ECG-based autonomic dysfunction in adults with prediabetes and diabetes in the DPPOS, more so for some glycaemic markers and in women.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":"10743-10752"},"PeriodicalIF":6.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13646355/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148872248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes.","authors":"Giacomo Ruotolo, Charles Harris, Yanzhu Lin, Jonathan M Wilson, Valentina Pirro, Kevin L Duffin, Melissa K Thomas, Mark L Hartman, Ciara O' Neill, Tamer Coskun, Zvonko Milicevic, Axel Haupt, Naveed Sattar, Stephen J Nicholls","doi":"10.1111/dom.71200","DOIUrl":"10.1111/dom.71200","url":null,"abstract":"<p><strong>Aims: </strong>To further characterise the effects of retatrutide on cardiometabolic risk, lipoprotein and inflammatory biomarkers were assessed post hoc in phase 2 trials of adults with obesity/overweight with or without type 2 diabetes (T2D).</p><p><strong>Materials and methods: </strong>Data were analysed from two randomised, double-blind, placebo-controlled phase 2 trials. In Study 1, adults with obesity/overweight and T2D received once-weekly retatrutide (0.5/4/8/12 mg), dulaglutide (1.5 mg) or placebo for 36 weeks; in Study 2, adults with clinical obesity without T2D received retatrutide (1/4/8/12 mg) or placebo for 48 weeks. Fasting blood samples were collected at baseline and during treatment to assess lipids, apolipoproteins, lipoprotein particle subclasses and inflammatory biomarkers. Mixed models for repeated measures estimated placebo-adjusted change from baseline. Statistical significance was defined as a false discovery rate-adjusted p < 0.05.</p><p><strong>Results: </strong>Mean body mass index was 35.4 kg/m² (Study 1) and 37.4 kg/m² (Study 2). In both studies, retatrutide was associated with significant reductions in non-high-density lipoprotein cholesterol (Study 1: up to -21.0%, Study 2: up to -26.9%), apolipoprotein B (-21.4%, -24.2%), total triglyceride-rich lipoprotein particles (-22.5%, -33.7%), large triglyceride-rich lipoprotein particles (-84.4%, -76.6%), triglyceride-rich lipoprotein cholesterol (-29.4%, -38.6%), total low-density lipoprotein particles (-19.7%, -23.5%) and small low-density lipoprotein particles (-32.6%, -32.3%). Retatrutide was associated with significant reductions in high-sensitivity C-reactive protein (-54.8%) and interleukin-6 (-29.6%) in Study 2 but not Study 1.</p><p><strong>Conclusions: </strong>In adults with obesity/overweight, with or without T2D, retatrutide treatment was associated with reductions in atherogenic lipoproteins and inflammatory biomarkers linked to cardiovascular disease risk.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov numbers NCT04881760 and NCT04867785.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":"10183-10194"},"PeriodicalIF":6.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13646367/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148786325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic and Clinical Determinants of Variation in Drug Response in Type 2 Diabetes: Insights From the Scottish and UK Biobank Cohorts.","authors":"S Garg, R Kitchen, R Gupta, L Donnelly, E R Pearson","doi":"10.1111/dom.71262","DOIUrl":"10.1111/dom.71262","url":null,"abstract":"<p><strong>Objective: </strong>Treatment response in type 2 diabetes (T2D) varies widely among individuals. This study aimed to quantify the contributions of clinical characteristics and genetic predisposition as measured through partitioned polygenic risk scores (pPRS) to variation in glycemic response to glucose-lowering therapies.</p><p><strong>Research design and method: </strong>We analysed data from two population-based cohorts: the Genetics of Diabetes Audit and Research in Tayside Scotland (GoDARTS) and the UK Biobank (UKBB). GoDARTS included 41 802 patients who initiated one of six major drug classes, of whom 11 615 had available genotype data. UKBB contributed 9371 individuals, including 8293 with genetic data. The primary outcome was glycaemic response, defined as the change in HbA1c 12 months after treatment initiation. Variables included demographic and clinical factors (age, sex, BMI, baseline HbA1c, kidney and liver function markers) and 14 pPRS representing T2D-related biological pathways. Linear regression models were fitted within each cohort and drug class (metformin, sulfonylureas, TZDs, DPP4i, SGLT2i, GLP-1RA), and effect estimates were combined using fixed-effect meta-analysis.</p><p><strong>Result: </strong>Baseline HbA1c was most strongly associated with glycemic response (p < 0.001). Older age was consistently associated with greater HbA1c reduction, while BMI and total cholesterol demonstrated drug-class-specific associations, with higher BMI associated with improved response to TZDs and higher total cholesterol generally associated with poorer glycaemic outcomes. Meta-analysis across GoDARTS and UK Biobank showed that higher overall T2D genetic risk was associated with greater HbA1c reduction with sulfonylureas (β = -0.46 mmol/mol, p = 0.013). Specific genetic profiles were also associated with drug responses, including β-cell function clusters with sulfonylureas (β = -0.57, p = 0.002), obesity-related variants with GLP-1RA (β = -1.49, p = 0.04), liver-lipid variants with SGLT2 inhibitors (β = -0.84, p = 0.05), and bilirubin pPRS with DPP-4 inhibitors (β = -0.69, p = 0.006).</p><p><strong>Conclusion: </strong>Both clinical and genetic factors significantly contribute to inter-individual variability in T2D drug response. Partitioned PRSs provide mechanistic insights into drug-specific pathways and have the potential to inform precision prescribing and optimise therapeutic outcomes in routine diabetes care.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":"10780-10794"},"PeriodicalIF":6.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13646362/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148872428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Oral PCSK9 Inhibitors in Adults With Hypercholesterolemia: An Updated and GRADE Assessed Systematic Review and Meta-Analysis of Randomised Controlled Trials.","authors":"Muhammad Huzaifa Khattak, Sohana Memon, Humaira Bibi, Irshad Munir Hassan, Javaria Gul, Kosar Ajmal, Aneeq Mahmood Khan, Danyal Ahmed, Ali Saqlain Saleem, Mohammad Bilal Yousuf, Yasir Mehmood, Hareem Ali, Mehr Afroz, Malik Muhammad Nasr Fayyaz, Tayyaba Ikram Qazi, Bilal Wazir Khan","doi":"10.1111/dom.71208","DOIUrl":"10.1111/dom.71208","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the efficacy and safety of oral PCSK9 inhibitors in adults with hypercholesterolemia by synthesizing evidence from randomised controlled trials.</p><p><strong>Methods: </strong>This systematic review and meta-analysis followed PRISMA guidelines and was registered on PROSPERO (CRD420261303350). PubMed, Embase and Scopus were searched from inception to March 2026 for randomised controlled trials comparing oral PCSK9 inhibitors with placebo in adults with hypercholesterolemia. Primary outcomes were changes in low-density lipoprotein cholesterol (LDL-C) and triglycerides. Secondary outcomes included other lipid parameters, adverse events and mortality. Random-effects models were used to calculate mean differences (MD) and risk ratios (RR) with 95% confidence intervals (CI). Quality of the included studies was assessed using the RoB2 tool and certainty of evidence was assessed using the GRADE approach.</p><p><strong>Results: </strong>Five randomised controlled trials (n = 4268) were included. Oral PCSK9 inhibitors significantly reduced LDL-C (MD -49.49 mg/dL; 95% CI -54.81 to -44.18; p < 0.00001) and triglycerides (MD -11.65 mg/dL; 95% CI -15.53 to -7.78; p < 0.00001). Significant reductions were also observed in non-HDL cholesterol, apolipoprotein B, lipoprotein(a) and total cholesterol. Dose-dependent effects were noted, with greater reductions at higher doses. No significant differences were observed in mortality or overall adverse events. Treatment discontinuation due to adverse events was lower with intervention.</p><p><strong>Conclusions: </strong>Oral PCSK9 inhibitors were associated with clinically meaningful improvements in multiple lipid parameters while maintaining a favourable short-term safety profile. However, the available evidence is derived primarily from short-term randomised trials evaluating surrogate lipid outcomes. Larger randomised trials with longer follow-up and cardiovascular outcome data are needed to better define the long-term clinical role of oral PCSK9 inhibitors.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":"10001-10017"},"PeriodicalIF":6.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148704662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Revised Obesity Definition Incorporating Excessive Fat Accumulation in Relation to Incident Cardiovascular Disease: A Large Prospective Cohort Study.","authors":"Lili Yang, Kai Mu, Yongfu Yu, Min Zhao, Bo Xi","doi":"10.1111/dom.71252","DOIUrl":"10.1111/dom.71252","url":null,"abstract":"","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":"10886-10890"},"PeriodicalIF":6.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148786119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Association Between NT-Pro BNP, Nephropathy and Endothelial Dysfunction in Patients With Type 2 Diabetes Mellitus.","authors":"Nursyahirah Ishak, Nur ' Aini Eddy Warman, Raja Ezman Faridz Raja Shariff, Xin Wee Chen, Rohana Abdul Ghani","doi":"10.1111/dom.71258","DOIUrl":"10.1111/dom.71258","url":null,"abstract":"<p><strong>Background: </strong>N-terminal pro-B-type natriuretic peptide (NT-Pro BNP) is an established biomarker of heart failure and has been recommended for cardiovascular risk stratification in type 2 diabetes mellitus (T2DM). However, its relationship with diabetic nephropathy and endothelial dysfunction across varying stages of kidney impairment remains unclear. This study examined the associations of NT-Pro BNP, renal impairment, albuminuria and endothelial dysfunction in patients with T2DM without overt heart failure.</p><p><strong>Methods: </strong>A comparative cross-sectional study was conducted among 192 adults with T2DM. Participants were stratified by KDIGO eGFR groups (≥ 90, 60-89, 30-59 mL/min/1.73m²). NT-Pro BNP was considered abnormal at a cut-off of ≥ 125 pg/mL. Albuminuria was categorized using the urinary albumin-to-creatinine ratio (uACR). Endothelial function was assessed by brachial artery flow-mediated dilatation (FMD). Logistic regression analysis was performed to identify independent factors of elevated NT-Pro BNP, with p-values < 0.05 considered statistically significant.</p><p><strong>Results: </strong>NT-Pro BNP levels were significantly higher in the lower eGFR groups compared with normal eGFR (204.3 vs. 96.8 vs. 62.2 pg/mL, p < 0001). A weak but significant positive correlation was observed between NT-Pro BNP and uACR (r = 0.31, p < 0.001). However, no significant association was found between NT-Pro BNP and FMD (p = 0.388). Following multivariable adjustments, older age (adjusted OR 1.14, 95% CI: 1.06-1.23, p < 0.001), higher systolic blood pressure (adjusted OR 1.05, 95% CI: 1.02-1.08, p = 0.010), lower eGFR (adjusted OR 0.97, 95% CI: 0.95-0.99, p = 0.003) and beta-blocker use (adjusted OR 4.65, 95% CI: 1.61-13.45, p < 0.001) were independently associated with elevated NT-Pro BNP.</p><p><strong>Conclusion: </strong>In patients with T2DM without overt heart failure, elevated NT-Pro BNP showed a statistically significant association with lower eGFR and higher albuminuria. Moderate to severe albuminuria becomes an independent factor for elevated NT-Pro BNP after adjustment excluding eGFR. The lack of association with endothelial dysfunction suggests that NT-Pro BNP may reflect different pathophysiological pathways. NT-Pro BNP may serve as a useful biomarker for early cardiovascular risk stratification and identification of individuals at risk of pre-heart failure in diabetic kidney disease.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":"10683-10695"},"PeriodicalIF":6.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148862767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to \"Obstructive Sleep Apnea Is Associated With Impaired Insulin Clearance and Hepatic Insulin Sensitivity in Paediatric Obesity\".","authors":"","doi":"10.1111/dom.71291","DOIUrl":"10.1111/dom.71291","url":null,"abstract":"","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":"10922"},"PeriodicalIF":6.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148872278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}